Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very interesting video, it tells me a lot, and says $RVVTF is far from done and does the PR update this morning. Also interesting that so many short sellers MM's are all over the L-2 data over playing their hand on a very red day. Even flippers world is and shorts are loading up the bid, heavy.
Interesting morning here. Every low life short seller MM is on L-2 molesting the ask trying to short and crash the stock but the longs are buying, and even PAUL moved his ask to $1, LMAO...
I started buying these early Christmas gifts already, and this price is steal of deal.
The so called bad news, is not really news, it just triggered a short MM raid that is failing. The good news I see is:
75% of the hospitalizations were in the Placebo group based on low dose for Bucillamine and 100% of the hospitalizations were from Placebo in the High dose Bucillamine trials.
"there were no deaths and four hospitalizations, of which three were from the placebo arm and one from the Bucillamine low dose group (300mg/day). No hospitalizations occurred in the Bucillamine large dose group (600mg/day), which was the dose suggested by the independent Data Safety Monitoring Board (“DSMB”) at the first interim analysis for the Post-dose selection phase of the Study. The one hospitalization event in the Bucillamine arm occurred in the low dose group (300mg/day), which was the dose abandoned after the first interim analysis per DSMB’s recommendation. Although the number of hospitalization events was small, it demonstrated a positive trend in the Post-dose selection phase of the Study. "
"However, based on preliminary analyses, the data demonstrated that for patients with oxygen saturation <96% at baseline, Bucillamine had a 29.1% improvement over placebo in time to normal oxygen saturation (SpO2)"
"Additional analyses of the Study data are ongoing, which could support certain strategic decisions on pursuing the development and commercialization of Bucillamine.
Based on the Study’s data analyzed to date, the Company is committed to advancing the clinical and commercial development of Bucillamine and is pursuing the following strategic initiatives"
They don't sound done to me. In fact they said:
Bucillamine 2.0: Reformulating Bucillamine in an intravenous and inhaled version to expand on its potential therapeutic utility targeting rare disorders such as ischemia-reperfusion injury (i.e. organ transplantation), acute respiratory distress syndrome, and potential medical countermeasures (i.e. terrorist attack with a biological, chemical, or radiological/nuclear material, or a naturally occurring emerging disease), that may come with regulatory incentives awarded by the FDA, such as emergency use authorization, orphan drug, fast track, and breakthrough therapy designations.
Pharmaceutical Partnerships: Work with interested pharmaceutical partners to pursue potential domestic and international regulatory approvals and new clinical studies for infectious, inflammatory and respiratory disorders.
Government Support: Seek out potential funding opportunities offered by, but not limited to, the Biomedical Advanced Research and Development Authority (BARDA), the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS).
We're basically done here. For me it doesn't pay to sell even though I lost my shirt. I will see what happens end of year to make a decision. Such a shame, so much promise. I guess another lesson learned from buying and holding a penny stock hoping to become rich, back to work I go.
“The Study did not achieve statistical significance on the clinical endpoints.”
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
https://finance.yahoo.com/news/revive-therapeutics-announces-results-phase-103000347.html
And now there is a Bucillamine video Jul 5, 2023
Bucillamine: A Unique Antirheumatic Drug with Different Properties and Possible Mode of Actions
that's about it
You obviously have not done any DD on PharmaTher. Check it out!
LOLOL....This sounds like the magic bullet theory. Is this all you got? PharmaTher is a 14 cent stock playing the same string investors along game MF is playing. You bet they're in the same building, like organized crime working together to pick your pocket. In 3 years you guys still haven't figured this out yet have you? Unbelievable.
With the price below .04. Hope is all you got here
Wait until Gov and Benson see your post, they'll bash you for saying anything positive about Revive.
Thanks for sharing. It's taking a little longer than I expected to review and release the data, but I hope things are moving forward behind the scenes, and we will all benefit at some point.
Long trailer
Thanks for the post! We wait.
Bullish case from Hattrick on Stocktwits
Hattrick3
16m
@Dirtymartini66 as frustrating as it’s been, this is far from over. No solutions are available, the Covid Therapeutic revenue projections are well over $30 billion in a few short years. Piles of money to be made. Start connecting the dots, the “sister” company Pharma Ther has just signed an agreement with Virtruvias Therapeutics out of Alabama. They have a CEO who has been in the business for decades and their Director worked for Johnson and Johnson for decades. They are also experts in the generic space. Phrrf is down the hall from Revive and they own a large chunk of Revive shares, enough to pay for their Ketarx trial when it launches if Revive can do something with Buci. Way too much money to be made and a drug that by every measurement has worked in every study that’s been done to date; trial data is coming. Is it possible that it doesn’t go any further; yep! Just not probable with the $$$ on the table for the company that has a Covid therapeutic; the drug works.
Bullish
Lemmings gonna lemming
Yep…all you can do is laugh at this point.
Pure manipulation by the MM's looking at the tiny trading action so far today. Should be made illegal once and for all. Oxygen thieves those responsible.
A very nice green day. Up 10% from Friday's close. Better than a knee in the bollocks.
Looks like a good price to buy more shares $RVVTF IMO
It doesn’t matter what dude of the political fence politicians are on. They’re all corrupt and are generally motivated by who or what I directly lives their financial means. Very few are authentic “do gooders”.
Jmho!
Which isn’t worth much …
FYI...The PDUFA fees that Pennyworld just mentioned as a source of bribery and corruption was signed into law by George HW Bush during his era.
Of it is corrupt! They take bribes by way of the PDUFA fees. Unfortunately the government has enabled them to become corrupt.... all legal. Just unethical. That is our politicians at work! I'm sure that there are some political kickbacks in there buried somewhere.
Want proof. How about undercover operation on tape. Here is the link. Scroll to the bottom and watch Part 1 and Part 2. https://www.projectveritas.com/
Not according to certain ""knowledgeable"" revive commentators.....apparently everything the fda, cdc and nih had/have been doing for decades, with special focus on their covid response, has always been open and above board.
To be succinctly direct, such as these obviously have no relationship with reality.
Still holding & hoping,why not, down so much it don`t really matter.
CW....I`m with you,thought I would be living the high life by now but still
digging ditches. Doing a sewer & water project at Abbott Labs in my area
thinking about telling them I will do the job for free if they put a offer in to buy
Revive for 5 billion.
I doubt he knows whats its like about working your as...off physically at least just chilling in office since he got some degree lol...sorry don't want to be negative. Yea I come home dirty from machinist work still wearing my n95 as 2 others ... but this is why I'm holding as I already know this possibility...
Many know he has 40 plus years bio tech investing.
Wait until you see the Data. It could very well be worth several hundred million dollars. Stock price reflects busted endpoints, not the data. Watch and learn.
— Rex Wiggins (@RexWiggins12) June 9, 2023
I hope Michael Frank worked his a$$ off today because I did with over 100 degree heat index. Unfortunately, I may have to do this for two more years if things don't change soon.
This is very old news. Dr Fahy said this about bucillamine years ago.
The Golden Knights are up 3 games to 1 and are the best team on paper, your twisted logic says we should cancel game 5 and hand them the Cup...right? Your misguided belief that research equals a clinical trial is delusional and completely out of touch with any semblance of reality.
Cool it snoop. If you want to sue anyone then sue frank for screwing up this trial as bad as he has. If the drug is so good then he really screwed the pooch by only getting a little over 700 people in this trial. The usual people here will blame the trial managers but frank is ceo so it falls back on him. He can’t take credit for anything if he is unwilling to take responsibility for the failures.
The establishment is corrupt. That's WTF is going on. Plain and simple.
WTH is going on here? WTH is wrong with the FDA!! Did anyone see this?
The researchers found that Omicron variants were particularly sensitive to an antioxidant called bucillamine, which is in a Phase 3 clinical trial by Revive Therapeutics to evaluate its safety and efficacy.
https://www.utoronto.ca/news/u-t-researchers-find-vulnerability-covid-19-variants-reduces-transmissibility
We all should sue the FDA for F up our Money. The FDA's failure to approve bucillamine despite favorable study results is extremely aggravating. This is the third time I see a study has had a positive light on bucillamine!!
News / announcements could drop any day. We would think that potential deals involving Revive's (patented) "Bucillamine" are being discussed in parallel with the FDA process. Plus we should remember that Bucillamine is not only a potential treatment for Covid symptoms but also proven to be very effective for Rheumatoid Arthritis for example. If the FDA does not swing our way for a Covid treatment after all, this whole process has at least significantly increased exposure for, and the knowledge of, Bucillamine on the big stage.
Exactly so!!!......small ""bites"" do add up over time and as evidenced by the fda's return to selectively lacking urgency re drug approvals, it may be some time before we experience significant pps movement..
With the last capital raise his 30k per month salary is safe. Revive shareholders are a cash cow for him. Why should he do anything?
I'm sorry for your losses. I feel your pain.
News bulletin numpt.......Ive long recouped my entire investment, and then some so where ye got this idiotic idea that "im down" is beyond me,.....been openly stating that for months now.
I have transformed from bullish to neutral. I slowly made the switch when this CEO dragged his feet 'out of the gate' when he got the green light to start the FDA P3 trial.
Bullshite.......from day one it was an anti-revive drone and only came here from the relief scam board to vent when that pos kept diluting its value into oblivion.
The hub's history has the receipts to expose those lies in full.......how embarrassing! lololsss
To recognize such a pattern and not exploit it would be foolish.
IMO
Let’s not get excited over the gains today. We have seen this over and over. Big rise one day and two days later we are below where we started at before the rise. The only thing that will make this thing rise and stay will be the pr stating mf has been booted out of the company for breaching his fiduciary duty to the shareholders. However we know that won’t happen because the board doesn’t have the balls to do it.
A very encouraging rise in PPS today for sure. Excited for this continuation.
I saw that this morning and see they now include a correction that Bucy is not FDA approved yet in the USA. That is quite a blunder to make in a press release and made me question the authentication of all the leg work put into the study. Errors like that can't happen and is embarrassing to the authors. However, as evidenced by gains today, people took interest. Cheers to seeing the actual 710 data any day now. We know this stuff is gold. The problem is nobody else does.
GLTA (even Snoopy)
Well said…couldn’t agree with you more.
There’s plenty of “disingenuous sincerity”. I'm right there with you. There are still some things to be hopeful for with this stock.
Yet, there is a constant barrage a lols, unnecessary drivel that seems to be aimed at poking fun of holders, rather than where the attention should be directed which is peeling back the layers to find the disconnects, short falls, and potential “corruption”.
This is like a few others that I hold, where you know that the stock should be doing at least a little better than what it is, but something fishy seems to be suppressing it. Not AT ALL to absolve leadership for missteps or failed opportunity taking. But sometimes theres more than just that.
I'm sorry for your losses. I feel your pain. I have transformed from bullish to neutral. I slowly made the switch when this CEO dragged his feet 'out of the gate' when he got the green light to start the FDA P3 trial. He had at least 6 months to prepare while waiting for the FDA signal. Once the green light came he was like ... Duhhh, what do I do next? It then took him months to get his feet off the ground. Then he posts a lot of garbage about the future of 'shrooms'.
IMO, there is a very high probability that the whole chase after EUA was smoke and mirrors in order to sustain a higher PPS for him to dilute into. Over time his shroom dreams fizzled so he became a little more interested in the FDA initiative, but it was too late. COVID is over, and his O/S is growing with no results to show the SH. It doesn't help matters that this CEO has ZERO communication skills.
I tell you how it is. Take it or leave it.
Youve spewed nothing but garbage about revive since 2020 so i find your ""bullish"" claim to be nothing but a laughable fabrication......the receipts are there for all to see!
After exposing that obvious LIE theres no need to respond to the remaining nonsense contained in that post...............
NOTE: Curious how some here claim to care about the treatment of shareholders that suffered huge losses, yet same poster(s) do nothing but appear here daily to gloat about said posters losses......how ironic. lololsss
#gobshites
My expectations of penny stock CEO's is very, very minimal. 98% of them are driven by greed, and they will screw over the SH if it benefits them. It is what it is. Swing Trading is the only smart way to trade penny stocks trading below a dime. 98% of the time the CEO's "End" goals are never met. They lure in investors to chase a very low probability dream. They get rich, the common SH loses. This is what I've learned the hard way. I was only in RVVTF for the unlikely event they would win the EUA. Without that, I'm seeing the glass as half empty. JMHO
Followers
|
339
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36630
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |